Becton, Dickinson and Company (BDX) recently completed the acquisition of HandyLab, Inc, an Ann Arbor, Michigan-based company that develops and manufactures automation platforms and molecular diagnostic assays. The transaction costs Becton $275 million.
The acquisition enables Becton to develop and commercialize its BD GeneOhm molecular assays on the HandyLab Jaguar platform, the first fully integrated molecular diagnostic system. The HandyLab instrumentation technology is considered to be an industry leading molecular diagnostic automation platform.
With the acquisition, Becton plans to market its BD GeneOhm molecular assays as the new BD Max system. Becton is a global leader in the treatment of healthcare associated infections (HAI). With growing concerns over HAI, hospitals are expanding their screening and testing programs and require automation systems to support their evolving needs.
Becton addresses HAI issues by supporting hospitals with its BD GeneOhm molecular testing product line and the HandyLab acquisition enables the company to expand the product line. The acquisition will boost demand for Becton’s molecular diagnostic products that will eventually drive the company’s top-line.
Becton, Dickinson and Company develops, manufactures and markets medical devices, supplies, laboratory equipment and diagnostic products globally. The company is a world leader in safety needle products. Becton competes with players like Baxter International (BAX), Johnson & Johnson (JNJ) and Abbott Laboratories (ABT).
We believe that Becton’s sound business model and product line should weather the current economic turbulence, and is capable of withstanding competitive pressure.
Read the full analyst report on “BDX”
Read the full analyst report on “BAX”
Read the full analyst report on “JNJ”
Read the full analyst report on “ABT”
Zacks Investment Research
